Rheumatoid Arthritis Clinical Trial
Official title:
Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis. A Randomized Controlled Trial.
Verified date | June 2017 |
Source | Glostrup University Hospital, Copenhagen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
In recent years there has been a growing interest in sedentary behaviour defined as
activities performed in sitting or lying position during waking hours. Sedentary behaviour
has been recognised as an independent risk factor for cardiovascular diseases and mortality.
A few intervention studies in older sedentary people and in overweight or obese adults have
demonstrated, that daily sitting time can be reduced through behavioural intervention.
Patients with rheumatoid arthritis (RA) have an increased risk for cardiovascular diseases,
partly caused by the rheumatic disease itself but also because of physical inactivity.
Studies have documented a positive effect of increasing physical activity on pain and
physical functioning in patients with RA. However, the studies also show, that the patients
find it difficult to maintain the increased physical activity levels over time. Previous
studies suggest that in promoting health among patients with mobility disability should not
solely focus on increasing moderate to vigorous physical activity but also target reduction
of sedentary behaviour and increase of light physical activity. In the present study we will
focus on reduction of daily sitting time and increase of light physical activity as this
approach may prove more feasible for patients with RA.
Objectives and hypothesises:
We hypothesise, that sedentary behaviour can be reduced in patients with RA through a
behavioural lifestyle change. In addition, we hypothesize, that reduction of daily sitting
time can have a positive effect on symptoms and general health in patients with RA.
The primary objective of the present intervention study is to investigate the effect of a
motivational counselling intervention on daily sitting time in adult men and women with RA.
Furthermore we want to investigate whether a reduction in daily sitting time is related to
reduction in pain and fatigue, reduced weight and waist circumference and improved quality
of life, physical function and improved cardiovascular biomarker levels (cholesterol and
blood pressure).
Study setting and allocation:
In total, 150 participants will be recruited from the rheumatology outpatient clinic at
Glostrup University Hospital, Denmark. The participants will be allocated to either an
intervention group (75) or a control group (75).
Intervention:
The intervention aims to support and strengthen the participants' belief in their own
ability to reduce their daily sitting time. The intervention will include 1) three
individual motivational counselling sessions (60-90 minutes), conducted by one of four
project nurses in combination with 2)Individual Short Text Messages (SMS). The counselling
sessions will focus on information about the positive health effects of reducing daily
sitting time and the participants' own goals of reducing their sitting time. Based on the
goals the participants will receive weekly SMS reminders.
Data collection:
Measurements on all participants will be done four times during 22 months; 1) at baseline,
2) 16 weeks after start (by the end of the intervention), 3) six months after end of
intervention and 4) 18 months after end of intervention. At each of the four visits the
participants fill in questionnaires regarding demographics, lifestyle, daily sitting time,
physical activity, physical function, pain , fatigue and quality of life. Furthermore, two
occupational therapists will measure the participants' blood pressure, height, weight and
waist circumference. At the same time a little monitor will be placed on the participants'
thigh, which they will carry for seven days. The monitor measures the participants' physical
activity level. The four measurements also include a blood sample from the participants in
order to measure cholesterol levels.
Status | Completed |
Enrollment | 150 |
Est. completion date | May 2016 |
Est. primary completion date | May 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Diagnosed with RA (defined by the American College Rheumatology (ACR) criteria) - Over the age of 18 years - Self-reported sitting time for five hours or more per day (measured by Physical Activity Scale, PAS 2.1) - Physical function score <2.5 (measured by Health Assessment Questionnaire, HAQ) - Informed consent - Understand and speak Danish - Access to mobile phone. Exclusion Criteria: - Severe physical disabilities (HAQ-score > 2.5) which would prevent them from reducing daily sitting time (e.g. use of wheelchair); - Pregnancy - Vigorous physical activity for more than eight hours a week (measured by PAS 2,1). |
Country | Name | City | State |
---|---|---|---|
Denmark | Research Unit of Nursing and Health Science, Glostrup University Hospital, Copenhagen, Denmark | Copenhagen | Glostrup |
Lead Sponsor | Collaborator |
---|---|
Glostrup University Hospital, Copenhagen |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cost data | For the analysis of intervention costs patients-related activities will be registered for each individual patient by the health care providers. In addition, data will be collected on time use related to each activity and relevant unit cost of resources. Other resource use and cost related to health care provisions will be obtained for each individual patient from the national health registries for hospitals, primary care and purchase of prescription medication from primary care pharmacies. These data will be obtained from the National Board of Health. | Baseline, 22 months | |
Primary | Changes in daily sitting time in hours and minutes | Changes in objectively measured daily sitting time will be obtained using an ActivPAL® Activity Monitor. This is a small and light uniaxial accelerometer-based device that is worn anteriorly on the upper right thigh and kept in place by waterproof dressing and adhesive tape. The monitor uses accelerometer-derived information about thigh position to estimate time spent in different body positions (i.e. sitting/lying, standing and walking). The activPAL monitor is currently considered the best choice for objective measurement of sitting/lying. Changes in self-reported sitting time at work and during leisure time will be measured by the Physical Activity Scale 2.1 (PAS 2.1), a modified version of the original PAS questionnaire, which has previously been validated against accelerometry, PA logs and maximum oxygen uptake. Respondents are asked to specify number of hours and minutes on an average 24-hour day spent on sitting at work and during leisure time. |
Baseline, 4 months, 10 months and 22 months | |
Secondary | Fatigue | The 20-item Multi-dimensional Fatigue Inventory (MFI 20) will be included to measure fatigue. MFI 20 consists of 20 statements such as "I feel enthusiastic" and classifies fatigues in five dimensions: 1) General fatigue 2) Physical fatigue 3) Mental fatigue 4) Reduced activity 5) Reduced motivation. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Pain | The Visual Analogue Scale (VAS) transforms the subjective experience of pain to a measurable size. The participant indicates his or her pain by putting a mark on the line where the ends are marked with "no pain" to "worst imaginable pain". | Baseline, 4 months, 10 months and 22 months | |
Secondary | Physical Function | Health Assessment Questionnaire (HAQ) is an instrument that contains 20 questions with four possible answers in eight categories of functions within the ADL (regular daily activities): dressing, rising, eating, walking, personal hygiene, to stretch for something, grab objects and everyday activities. In addition, the HAQ includes VAS scales pain, fatigue and general health. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Health Related Quality of Life (HR-QOL) | HR-QOL is assessed with 1) SF-36, which is a generic instrument consisting of 36 items divided into eight scales: physical function, role physical activity limitations, pain, general health, vitality, social function, role emotional activity limitations and mental health and 2) EuroQol (EQ-5D-5L), which is a standardized 5 item-instrument developed in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5 L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Self-efficacy | The General Self-Efficacy Scale assesses a general sense of perceived self-efficacy with the aim to predict coping with daily hassles and adaptation after experiencing stressful life events. The instrument is a 10-item scale with statements such as "I can usually handle whatever comes my way" and "I am confident that I could deal efficiently with unexpected events". The response format is 'not at all true', 'hardly true', 'moderately true', 'exactly true'. The instrument is translated and validated for Danish conditions. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Anthropometric measures | Weight is measured in light clothing without shoes to the nearest 0.1 kg; waist circumference is measured midway between the lower rib margin and the iliac crest to the nearest 0.5 centimetre, without any pressure to the skin and with an unstretched tape meter; hip circumference is measured at the point yielding the maximum circumference over the buttocks to the nearest 0.5 centimetre. The tape should be held in a horizontal plane touching the skin but not indenting the soft tissue. Body mass index (BMI, kg/m2) and waist-hip ratio are calculated. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Blood pressure | Blood pressure will be measured three times at the right upper arm (average of the three measurements) with the participant is in a sitting/lying position; rest 5-10 minutes before the measurements. | Baseline, 4 months, 10 months and 22 months | |
Secondary | Serum Lipids | Venous blood sample will be drawn (not fasting). Total cholesterol, high-density lipoprotein cholesterol (HDL), and triglycerides will be measured by an enzymatic method on the Vitros 5.1 FS from Ortho Clinical Diagnostics. Low-density lipoprotein cholesterol (LDL) and very low-density lipoprotein cholesterol (VLDL) will be calculated by the following formulae (VLDL=Triglyceride x 0.45; LDL=Total cholesterol - HDL + VLDL). Furthermore, C-reactive protein (CRP) and HbA1c will be measured on Vitros 5.1 FS and G8 HPLC Analyzer from TOSOH. | Baseline, 4 months, 10 months and 22 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |